Sound View Wealth Advisors Group LLC Increases Holdings in Krystal Biotech, Inc. $KRYS

Sound View Wealth Advisors Group LLC lifted its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS) by 28.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,947 shares of the company’s stock after acquiring an additional 432 shares during the period. Sound View Wealth Advisors Group LLC’s holdings in Krystal Biotech were worth $268,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Krystal Biotech by 173.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 575,506 shares of the company’s stock valued at $103,764,000 after acquiring an additional 365,304 shares during the period. Nuveen LLC purchased a new stake in Krystal Biotech during the first quarter valued at approximately $42,223,000. Braidwell LP boosted its position in shares of Krystal Biotech by 99.9% during the first quarter. Braidwell LP now owns 400,744 shares of the company’s stock valued at $72,254,000 after buying an additional 200,244 shares during the period. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Krystal Biotech during the first quarter valued at $33,455,000. Finally, 1832 Asset Management L.P. purchased a new stake in shares of Krystal Biotech in the first quarter valued at approximately $24,521,000. 86.29% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

KRYS has been the topic of a number of recent analyst reports. Guggenheim set a $224.00 price target on shares of Krystal Biotech and gave the company a “buy” rating in a report on Friday, October 17th. Bank of America raised their price target on shares of Krystal Biotech from $182.00 to $255.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Weiss Ratings reissued a “hold (c)” rating on shares of Krystal Biotech in a report on Wednesday, October 8th. Chardan Capital upped their target price on Krystal Biotech from $216.00 to $220.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $240.00 price target on shares of Krystal Biotech in a research report on Monday, September 15th. Six equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $228.14.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $199.53 on Tuesday. The firm has a market capitalization of $5.79 billion, a P/E ratio of 29.91 and a beta of 0.65. The stock has a 50-day simple moving average of $175.59 and a two-hundred day simple moving average of $154.09. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $212.98.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $1.54. The firm had revenue of $97.80 million for the quarter, compared to the consensus estimate of $93.72 million. Krystal Biotech had a return on equity of 19.36% and a net margin of 53.30%. As a group, analysts forecast that Krystal Biotech, Inc. will post 6.14 earnings per share for the current year.

Krystal Biotech Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).